Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
**Background:** Pulmonary arterial hypertension (PAH) is a disease characterized by dyspnea, fatigue, chest pain and syncope. As there is no known cure for PAH, the goal of treatment is to control symptoms and slow disease progression. Sildenafil, a phosphodiesterase-5 inhibitor, has been indicated...
Saved in:
Main Authors: | Ariel Berger, John Edelsberg, Simon Teal, Marko A. Mychaskiw, Gerry Oster |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2014-02-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://jheor.org/article/9871-use-of-sildenafil-in-pulmonary-arterial-hypertension-findings-from-a-u-s-healthcare-claims-database |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of Sildenafil and Vitamin E on Paraquat-Induced Pulmonary Fibrosis in Rats
by: Fouziyeh Siahpour, et al.
Published: (2024-12-01) -
Arduous management in treatment of elderly patient with pulmonary arterial hypertension and cardiopulmonary comorbidities
by: Yu Enomoto, et al.
Published: (2025-01-01) -
Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
by: Ci Song, et al.
Published: (2022-06-01) -
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
by: Richard Channick, MD, et al.
Published: (2025-02-01) -
Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension
by: Heather L. Clark, et al.
Published: (2025-02-01)